Today

Smith Micro Software registered 18.2 million shares for resale, representing a substantial overhang from convertible notes and warrants.

EKSO BIONICS HOLDINGS, INC.'s S-1 registration statement became effective; investors should review the original registration filing for securities, holders, and transaction terms.

AGILITI, INC. \DE's S-1/A registration statement became effective; investors should review the original registration filing for securities, holders, and transaction terms.

Agiliti, Inc. updated its S-1/A filing with a proposed IPO price range of $18.00 to $20.00 per share for 26.3 million shares, aiming to raise up to $526.3 million.

Kodiak Robotics filed an S-4 for its business combination with Ares Acquisition Corporation II.

Cycurion registered 25.9 million shares for resale, including ELOC and convertible stock, representing a 225.6% overhang against current outstanding shares.

Mondee Holdings registered a substantial resale of 75.5 million shares, representing 92.8% of outstanding Class A Common Stock, creating significant potential overhang.

Graf Global Corp. filed an amendment to its business combination agreement with BIG3 HoldCo LLC.

Added IPO shares expand the offering size; final pricing and underwriter option exercise determine the real impact.

Added IPO shares expand the offering size; final pricing and underwriter option exercise determine the real impact.

Forgent Power Solutions registered an additional 9.95 million Class A common shares under Rule 462(b), expanding its total registered pool to 50.2 million shares.

Artelo Biosciences' S-1/A details a mixed offering of 1.64 million shares or pre-funded warrants, indicating substantial potential dilution.

Linkers Industries filed an F-1 for Units with zero-exercise Series B Warrants, posing significant dilution risk to Class A Ordinary Shareholders.

Can-Fite BioPharma registered a mixed offering of ADSs and warrants, with significant potential dilution and variable terms.

IES Holdings filed a universal shelf registration to offer common stock, preferred stock, debt, and warrants from time to time, with specific terms to be determined later.

Altimmune registered an additional $65 million for its universal shelf, increasing its future offering capacity by 23.3% of its market cap, but no immediate sale is planned.

Akari Therapeutics registered 5.99 million ADSs for resale by selling shareholders, representing a 523.9% potential overhang, with the company receiving no proceeds from the resale itself.

Veea Inc. filed a universal shelf registration for up to $75.0 million, representing 873.9% of its current market cap. This creates significant future dilution potential, though no active sale is launched yet.

Xilio Therapeutics updated its ATM program to $14.5 million, representing 25.2% of its public float, with sales through Leerink Partners under a larger $250 million shelf registration.

Rubico Inc. registers a mixed offering of up to 3.34 million Units, various warrants, and 50 million equity line resale shares, posing significant potential dilution.